436 related articles for article (PubMed ID: 31028801)
1. New insights towards mesoporous silica nanoparticles as a technological platform for chemotherapeutic drugs delivery.
Sábio RM; Meneguin AB; Ribeiro TC; Silva RR; Chorilli M
Int J Pharm; 2019 Jun; 564():379-409. PubMed ID: 31028801
[TBL] [Abstract][Full Text] [Related]
2. Advances in Functionalized Mesoporous Silica Nanoparticles for Tumor Targeted Drug Delivery and Theranostics.
Zhang W; Liu M; Liu A; Zhai G
Curr Pharm Des; 2017; 23(23):3367-3382. PubMed ID: 27784244
[TBL] [Abstract][Full Text] [Related]
3. Tailored Mesoporous Silica Nanoparticles for Controlled Drug Delivery: Platform Fabrication, Targeted Delivery, and Computational Design and Analysis.
She X; Chen L; Yi Z; Li C; He C; Feng C; Wang T; Shigdar S; Duan W; Kong L
Mini Rev Med Chem; 2018; 18(11):976-989. PubMed ID: 27145854
[TBL] [Abstract][Full Text] [Related]
4. A Review on Recent Technologies and Patents on Silica Nanoparticles for Cancer Treatment and Diagnosis.
Gupta A; Kushwaha SS; Mishra A
Recent Pat Drug Deliv Formul; 2020; 14(2):126-144. PubMed ID: 32928094
[TBL] [Abstract][Full Text] [Related]
5. Multifunctional Mesoporous Silica Nanoparticles for Cancer Therapy and Imaging.
Dilnawaz F
Curr Med Chem; 2019; 26(31):5745-5763. PubMed ID: 29714137
[TBL] [Abstract][Full Text] [Related]
6. Lactosaminated mesoporous silica nanoparticles for asialoglycoprotein receptor targeted anticancer drug delivery.
Quan G; Pan X; Wang Z; Wu Q; Li G; Dian L; Chen B; Wu C
J Nanobiotechnology; 2015 Feb; 13():7. PubMed ID: 25643602
[TBL] [Abstract][Full Text] [Related]
7. A pH-responsive dissociable mesoporous silica-based nanoplatform enabling efficient dual-drug co-delivery and rapid clearance for cancer therapy.
He Y; Shao L; Usman I; Hu Y; Pan A; Liang S; Xu H
Biomater Sci; 2020 Jun; 8(12):3418-3429. PubMed ID: 32405634
[TBL] [Abstract][Full Text] [Related]
8. Targeted and controlled drug delivery by multifunctional mesoporous silica nanoparticles with internal fluorescent conjugates and external polydopamine and graphene oxide layers.
Tran AV; Shim K; Vo Thi TT; Kook JK; An SSA; Lee SW
Acta Biomater; 2018 Jul; 74():397-413. PubMed ID: 29775731
[TBL] [Abstract][Full Text] [Related]
9. Targeted Mesoporous Silica Nanocarriers in Oncology.
Baeza A; Vallet-Regi M
Curr Drug Targets; 2018 Feb; 19(3):213-224. PubMed ID: 27262488
[TBL] [Abstract][Full Text] [Related]
10. Mesoporous silica nanoparticles in medicine--recent advances.
Mamaeva V; Sahlgren C; Lindén M
Adv Drug Deliv Rev; 2013 May; 65(5):689-702. PubMed ID: 22921598
[TBL] [Abstract][Full Text] [Related]
11. Recent advancements in mesoporous silica nanoparticles towards therapeutic applications for cancer.
Li T; Shi S; Goel S; Shen X; Xie X; Chen Z; Zhang H; Li S; Qin X; Yang H; Wu C; Liu Y
Acta Biomater; 2019 Apr; 89():1-13. PubMed ID: 30797106
[TBL] [Abstract][Full Text] [Related]
12. Enhanced Blood Suspensibility and Laser-Activated Tumor-specific Drug Release of Theranostic Mesoporous Silica Nanoparticles by Functionalizing with Erythrocyte Membranes.
Su J; Sun H; Meng Q; Zhang P; Yin Q; Li Y
Theranostics; 2017; 7(3):523-537. PubMed ID: 28255347
[TBL] [Abstract][Full Text] [Related]
13. Chemoresponsive smart mesoporous silica systems - An emerging paradigm for cancer therapy.
Murugan B; Krishnan UM
Int J Pharm; 2018 Dec; 553(1-2):310-326. PubMed ID: 30316004
[TBL] [Abstract][Full Text] [Related]
14. Drug delivery/imaging multifunctionality of mesoporous silica-based composite nanostructures.
Chen Y; Chen H; Shi J
Expert Opin Drug Deliv; 2014 Jun; 11(6):917-30. PubMed ID: 24746014
[TBL] [Abstract][Full Text] [Related]
15. Co-Delivery of Epirubicin and siRNA Using Functionalized Mesoporous Silica Nanoparticles Enhances In vitro and In vivo Drug Efficacy.
Hanafi-Bojd MY; Jaafari MR; Ramezanian N; Abnous K; Malaekeh-Nikouei B
Curr Drug Deliv; 2016; 13(7):1176-1182. PubMed ID: 26718488
[TBL] [Abstract][Full Text] [Related]
16. Development of mesoporous silica-based nanoparticles with controlled release capability for cancer therapy.
Mekaru H; Lu J; Tamanoi F
Adv Drug Deliv Rev; 2015 Dec; 95():40-9. PubMed ID: 26434537
[TBL] [Abstract][Full Text] [Related]
17. Advances in mesoporous silica nanoparticles for targeted stimuli-responsive drug delivery: an update.
Castillo RR; Lozano D; González B; Manzano M; Izquierdo-Barba I; Vallet-Regí M
Expert Opin Drug Deliv; 2019 Apr; 16(4):415-439. PubMed ID: 30897978
[TBL] [Abstract][Full Text] [Related]
18. Cancer-targeted and intracellular delivery of Bcl-2-converting peptide with functional macroporous silica nanoparticles for biosafe treatment.
Wu Y; Ge P; Xu W; Li M; Kang Q; Zhang X; Xie J
Mater Sci Eng C Mater Biol Appl; 2020 Mar; 108():110386. PubMed ID: 31923940
[TBL] [Abstract][Full Text] [Related]
19. The Bioimaging Applications of Mesoporous Silica Nanoparticles.
Pratiwi FW; Kuo CW; Wu SH; Chen YP; Mou CY; Chen P
Enzymes; 2018; 43():123-153. PubMed ID: 30244805
[TBL] [Abstract][Full Text] [Related]
20. Advances in mesoporous silica nanoparticles for targeted stimuli-responsive drug delivery.
Baeza A; Colilla M; Vallet-Regí M
Expert Opin Drug Deliv; 2015 Feb; 12(2):319-37. PubMed ID: 25421898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
